Ashlee H. wrote: The other options I'm not crazy about - go back on FOLFIRI + Avastin which gives me no quality of life. Go on Gemzar + Xeloda - I've known no one who was helped by Gemzar and Xeloda hurts my heart.
Gemzar would be off label... since your onc is willing to go the off label route, what about Nexavar (sorafenib)? They do have results with Nexavar + Xeloda (with Xeloda at lower doses, your heart may be fine...). They feel Nexavar + Xeloda could be an alternative to Stivarga. I'll copy an old post (for when you're back form your mini stay at the big house : ):
Combining SOR and CAP increases survival in advanced colorectal cancerMonday
Feb 03, 2014 | Reuters
"We studied 92 patients with advanced colorectal cancer (metastatic or with an unresectable local recurrence)
who had received every single or combined medication available for this condition," explained Dr. Alain Hendlisz, lead researcher and head of the GI unit in the Medical Oncology Department at the Institut Jules Bordet in Brussels.
CAP [= capecitabine = Xeloda] was given at 1700 mg/m²/day (D), for two out of three weeks;
SOR [sorafenib] was administered at 600mg/D for the first cycle, then at 800mg/D until progression or unacceptable toxicity.
"Based on earlier trials,
we should have expected that only 30-35% of the patients would be alive after six months, if the treatment had no activity in this disease. However, 71% of the patients included in the trial were alive at six months, which is a remarkable achievement," Hendlisz told Reuters.
(...)
"This could be another active regimen for a group of patients that is ready for more treatment," Dr. Krishnamurthi said. "It's hard to show an improvement in survival for colorectal cancer, and this study did it, however, it is a small study and the results are not definitive. Regorafenib [Stivarga], which has gone through Phase III studies, is very similar.
Further study of the SOR-CAP combination is needed to know if it could eventually replace regorafenib [Stivarga]."
More:
http://www.newsdaily.com/health/34231f6 ... tal-cancerThese previous news come from Brussels (Belgium); this is an older article about the phase 1 of that trial:
Safety and Pharmacokinetics of Sorafenib Combined With Capecitabine in Patients With Advanced Solid Tumors: Results of a Phase 1 Trial (pubished online 12 MAR 2013).
But there is also this ongoing trial at the University of Florida, with the same agents:
Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer and, from that trial, these are the results presented at the 2013 Gastrointestinal Cancers Symposium
Phase II study of sorafenib and capecitabine (SorCape) in previously treated metastatic colorectal cancer (mCRC): NCT01471353